Specialty Pharmacy

Pharmacists can expect to answer patient questions related to HIV more often in the beginning of the week.

Merck's once-daily treatment regimen of grazoprevir and elbasvir may bring added competition to HCV drug market.

Introduction of protein to pancreatic cancer cells causes them to revert back to normal.

Gene may help identify clue to separation of overactive and underactive immune activity.

Partnership will inform and educate industry stakeholders and policymakers about the unique demands specialty medicines place on pharmacies pharmacists and patients.

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses the changing role of specialty pharmacy in cancer treatment.

Nearly 30% of total biologic drug costs paid out-of-pocket.

Taking over-the-counter supplements beyond the recommended amount could increase cancer risk.

Suppression of Wnt signaling pathway shows promise.

Pharmacists don't have to learn American Sign Language to effectively communicate with deaf and hard-of-hearing patients, but they do need to improve their knowledge, attitudes, and comfort levels.

Despite increases in liver cirrhosis hospitalizations over the years, the cirrhotic inpatient death rate has dropped 41%.

Long term implications result when patients stop taking disease-modifying drugs.

An antiviral and anti-cancer drug combination was 100% effective in preclinical trials.

Top stories of the week on Specialty Pharmacy Times from April 20 to April 24.

Wiskott-Aldrich treatment shows robust clinical effect.

Re-engineering antibodies allows them to selectively kill tumors.

COPD patients must clear major hurdles before and after initiating nebulizer use.

Catamaran chief medical officer discusses various trends that will impact specialty medications into the future.

Topical medications that treat skin conditions prompt stem cells in the brain to repair damage.

Regulating PD-L1 protein that helps cancer evade immune system suggests new therapeutic approach.

Patients should be counseled that there is no safe level of alcohol consumption.

The FDA today approved a second-line treatment for metastatic colorectal cancer.

The FDA has awarded Breakthrough Therapy status to crizotinib (Xalkori) for ROS1-positive non-small cell lung cancer.

Novel pathway regulating immune cell movement may help eliminate debilitating effects of several serious diseases.

Pushing treatment with natalizumab from 4 weeks up to 8 weeks shows promising results.

Researchers determine mechanism for poor survival rates in African American patients with estrogen-receptor positive breast cancer.

Pharmacists in North Dakota came closer to attaining provider status when state Gov. Jack Dalrymple recently signed 4 laws recognizing pharmacists as providers.

Mild exercise found to improve fatigue and depression.